Catalytic covalent inhibition of cyclooxygenase-1 by a biomimetic acyltransferase

Bioorg Med Chem. 2022 Oct 15:72:116973. doi: 10.1016/j.bmc.2022.116973. Epub 2022 Aug 27.

Abstract

Covalent binding enzyme inhibitors have grown in acceptance in therapeutic discovery. Several recent examples of protein-targeting acyl-transfer catalysts covalently modify protein targets in cellular systems but generally do not affect protein function. In this study, a small molecule has been developed for the first time that can achieve catalytic covalent inhibition of the inflammatory response enzyme, cyclooxygenase-1, in cells using only endogenous acetyl-CoA as a co-substrate. By utilizing a catalytic inhibitor which can self-regenerate, a sustained inhibitory response is achieved in cells compared to the analogous non-catalytic covalent cyclooxygenase antagonist, acetylsalicylic acid (aspirin).

Keywords: Acyl-transfer catalysis; Catalytic covalent inhibitor; Covalent inhibitor; Cyclooxygenase; Protein acetylation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetyl Coenzyme A
  • Acyltransferases* / metabolism
  • Aspirin
  • Biomimetics*
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology

Substances

  • Enzyme Inhibitors
  • Acetyl Coenzyme A
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Acyltransferases
  • Aspirin